Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog

Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog

Abstract Background Occult (or atypical) hyperadrenocorticism (HAC) shows clinical signs and laboratory abnormalities similar to classic hyperadrenocorticism, but normal signs in routine screening tests such as the corticotropin (ACTH) stimulation test and low‐dose dexamethasone suppression test (LD...

Full description

Bibliographic Details
Main Authors:	Su‐Min Park, Kyeong‐Bo Kim, Woo‐Jin Song, Hwa‐Young Youn
Format:	Article
Language:	English
Published:	Wiley 2021-07-01
Series:	Veterinary Medicine and Science
Subjects:	17‐hydroxyprogesterone mitotane occult hyperadrenocorticism
Online Access:	https://doi.org/10.1002/vms3.482

Similar Items

Evaluation of compounded trilostane packets for dogs with naturally occurring hyperadrenocorticism
by: Sookin Nam, et al.
Published: (2021-07-01)

Trilostane monitoring in canine hyperadrenocorticism: can basal cortisol measurement replace the ACTH stimulation test?
by: Theodora Tsouloufi, et al.
Published: (2021-09-01)

Evaluation of pressor sentivity to norepinephrine infusion in dogs with iatrogenic hyperadrenocorticism
by: Martinez, Nivia Ivellise
Published: (2014)

Assessment of Hypercoagulability in Canine Pituitary-Dependent Hyperadrenocorticism
by: Park, Fiona Marie
Published: (2012)

Metformin reduces insulin resistance and the tendency toward hyperglycaemia and dyslipidaemia in dogs with hyperadrenocorticism
by: Diego Daniel Miceli, et al.
Published: (2018-05-01)

Clinical results of the use of mitotane for adrenocortical carcinoma
by: A.A. Kasperlik-Zaluska
Published: (2000-10-01)

Cibles moléculaires du Mitotane : Implications pour le traitement du corticosurrénalome
by: Hescot, Ségolène
Published: (2015)

An activating mutation in the CRHR1 gene is rarely associated with pituitary-dependent hyperadrenocorticism in poodles
by: Viviani De-Marco, et al.

Overexpression of 11β-hydroxysteroid dehydrogenase 1 in visceral adipose tissue and underexpression of endothelial nitric oxide synthase in the adrenal cortex of dogs with hyperadrenocorticism
by: Diego Daniel Miceli, et al.
Published: (2018-03-01)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
by: Soraya Puglisi, et al.
Published: (2020-03-01)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
by: Jonathan Poirier, et al.
Published: (2020-03-01)

Decrease of nitric oxide and increase in diastolic blood pressure are two events that affect renal function in dogs with pituitary dependent hyperadrenocorticism
by: Patricia N. Vidal, et al.
Published: (2018-03-01)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
by: Soraya Puglisi, et al.
Published: (2019-11-01)

Laboratory assessment of trilostane treatment in dogs with pituitary‐dependent hyperadrenocorticism
by: Carolina Arenas Bermejo, et al.
Published: (2020-07-01)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01)

Mitotane (op’DDD) restores growth and puberty in nine children with Cushing’s disease
by: Emmanuelle Motte, et al.
Published: (2018-11-01)

Antibody Response to Canine Parvovirus Vaccination in Dogs with Hyperadrenocorticism Treated with Trilostane
by: Michèle Bergmann, et al.
Published: (2020-09-01)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
by: Elisa Rossini, et al.
Published: (2021-06-01)

Stability of Compounded Trilostane Suspension in Cod Liver Oil
by: Crosby, Jesse, et al.
Published: (2017)

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens
by: Thien B. Tran, et al.
Published: (2018-04-01)

Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
by: Yoann Cazaubon, et al.
Published: (2019-10-01)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
by: Vittoria Basile, et al.
Published: (2021-04-01)

Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant Acinetobacter baumannii: A Metabolomic Study
by: Thien B. Tran, et al.
Published: (2018-04-01)

Local advanced adrenocortical cancer with a long‐term recurrence‐free survival treated with complete surgical excision and adjuvant therapy with a very low‐dose mitotane
by: Yuumi Tokura, et al.
Published: (2020-11-01)

Adiposity is Associated with Decreased Serum 17-Hydroxyprogesterone Levels in Non-Diabetic Obese Men Aged 18–49: A Cross-Sectional Study
by: José Ignacio Martínez-Montoro, et al.
Published: (2020-11-01)

Cushing’s Syndrome – An epidemiological study based on a canine population of 21,281 dogs
by: Gaia Carotenuto, et al.
Published: (2019-02-01)

Tertiary hypothyroidism in a dog
by: Shiel Robert E, et al.
Published: (2007-02-01)

The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation
by: A A Kolomeytseva, et al.
Published: (2017-09-01)

Complete Remission of Advanced Adrenocortical Cancer Following Mitotane Monotherapy: A Case Report and Literature Review of Predictive Markers
by: Judit Tőke, et al.
Published: (2021-05-01)

The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells
by: Elaine Silveira, et al.
Published: (2018-03-01)

Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples
by: Giacomo Luci, et al.
Published: (2021-05-01)

Urine protein electrophoresis study in dogs with pituitary dependent hyperadrenocorticism during therapy with trilostane
by: Douglas S. Caragelasco, et al.

Mise en forme et amélioration de la biodisponibilité d'un anticancéreux destiné à la voie orale : exemple du mitotane
by: Attivi, David
Published: (2010)

Of 11 candidate steroids, corticosterone concentration standardized for mass is the most reliable steroid biomarker of nutritional stress across different feather types
by: Alexis Will, et al.
Published: (2019-10-01)

Adrenocortical carcinoma in a 6-month-old infant
by: Seema Rahar, et al.
Published: (2020-01-01)

Management of hirsutism
by: N K Agrawal
Published: (2013-01-01)

Adrenalectomy in dogs: retrospective study of 13 cases performed in Universidade Anhembi Morumbi Veterinary Hospital (2012-2015)
by: Tatiana Pacini, et al.
Published: (2017-12-01)

Effect of 17 α-Hydroxyprogesterone Caproate on the Prevention of Preterm Labor: A Randomized Controlled Trial Study
by: Hamed Jafarpour, et al.
Published: (2020-07-01)

Ectopic Cushing’s syndrome associated with a pheochromocytoma in a dog: a case report
by: Sungin Lee, et al.
Published: (2020-02-01)

Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study
by: Lidia Cerquetti, et al.
Published: (2019-11-01)

Cannot write session to /tmp/vufind_sessions/sess_kn6f0o8b2eguc3gl1nmce5pa7s